ストックスクリーナーアプリを入手
1.27
0.78%
-0.01
前日終値:
$1.28
開ける：
$1.36
24時間の取引高:
38,836
Relative Volume:
1.25
時価総額：
$2.30M
収益：
$12.99M
当期純損益:
$-27.83M
株価収益率:
-0.00623
EPS:
-203.7366
ネットキャッシュフロー:
$-26.98M
1週間 パフォーマンス:
-20.62%
1か月 パフォーマンス:
-33.51%
6か月 パフォーマンス:
-74.11%
1年 パフォーマンス:
-95.17%
1日の値動き範囲:
$1.26
$1.3699
1週間の範囲:
$1.2525
$1.74
52週間の値動き範囲:
$1.2525
$28.44
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Compare APVO vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.27 | 2.30M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
529.53 | 134.22B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.22 | 85.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.09 | 83.71B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
890.93 | 56.03B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.31 | 42.23B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting - FinancialContent
Two immune defenses are central to an approach Aptevo will present at a cancer meeting. - Stock Titan
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Treasure Coast News
Aptevo advances APVO-451 toward IND-enabling studies - BioWorld News
Aptevo Therapeutics (APVO) Advances Trispecific Therapies Amid C - GuruFocus
Aptevo advances trispecific cancer therapy manufacturing - Investing.com
Aptevo Advances Trispecific APVO451 Toward Clinical Development - accessnewswire.com
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Stock Titan
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Yahoo Finance
Aptevo Therapeutics (APVO) Edges Lower to $1.82 as Shares Hold Above $1.73 SupportFactor Timing - dars.gov.et
APVO StockImmuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - Mshale
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - Benzinga
Aptevo Therapeutics (NASDAQ: APVO) Registers 6.44M Shares for Holder Resale Following Warrant Exercises - kalkinemedia.com
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - GuruFocus
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com Nigeria
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com South Africa
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com UK
$Aptevo Therapeutics (APVO.US)$ [Strong][Smile][Heart][Rose][Leek] - Moomoo
Aptevo Therapeutics (APVO) Reports Promising AML Trial Results A - GuruFocus
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML - TipRanks
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com India
Aptevo reports 93% clinical benefit rate in AML trial subset - Investing.com
Aptevo Reports Strong Mipletamig Results in TP53-Mutated AML - ACCESS Newswire
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - FinancialContent
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? - Investing.com
Aptevo Therapeutics Inc. (APVO) Peer Comparison – Compare with Others - Value Research
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo (APVO) Momentum: Moves 10.07% Down to $2.41 for the Current Session; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingHagopian Line - vinanet.vn
APVO: Focusing on Three Key Areas of Development - Yahoo Finance
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com UK
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Yahoo Finance
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
44.31%
6.18%
大文字化:
|
ボリューム (24 時間):